Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
83% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. SRDX: No Debt )
SRDX' s 10-Year Cash to Debt Range
Min: 50.6   Max: No Debt
Current: No Debt

Equity to Asset 0.95
SRDX's Equity to Asset is ranked higher than
98% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. SRDX: 0.95 )
SRDX' s 10-Year Equity to Asset Range
Min: 0.74   Max: 0.96
Current: 0.95

0.74
0.96
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
98% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 115.25 vs. SRDX: No Debt )
SRDX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 36.06
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.53
SRDX's Operating margin (%) is ranked higher than
98% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.76 vs. SRDX: 33.53 )
SRDX' s 10-Year Operating margin (%) Range
Min: -20.11   Max: 51.75
Current: 33.53

-20.11
51.75
Net-margin (%) 27.02
SRDX's Net-margin (%) is ranked higher than
98% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. SRDX: 27.02 )
SRDX' s 10-Year Net-margin (%) Range
Min: -35.08   Max: 32.59
Current: 27.02

-35.08
32.59
ROE (%) 16.17
SRDX's ROE (%) is ranked higher than
87% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. SRDX: 16.17 )
SRDX' s 10-Year ROE (%) Range
Min: -13.66   Max: 21.78
Current: 16.17

-13.66
21.78
ROA (%) 14.88
SRDX's ROA (%) is ranked higher than
95% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. SRDX: 14.88 )
SRDX' s 10-Year ROA (%) Range
Min: -12.38   Max: 20.24
Current: 14.88

-12.38
20.24
ROC (Joel Greenblatt) (%) 111.09
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. SRDX: 111.09 )
SRDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18.81   Max: 181
Current: 111.09

-18.81
181
Revenue Growth (%) -1.80
SRDX's Revenue Growth (%) is ranked higher than
63% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. SRDX: -1.80 )
SRDX' s 10-Year Revenue Growth (%) Range
Min: -24.6   Max: 57.8
Current: -1.8

-24.6
57.8
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SRDX Guru Trades in Q2 2013

Paul Tudor Jones 13,700 sh (New)
Jim Simons 397,538 sh (+50.47%)
Joel Greenblatt 59,954 sh (+38.66%)
Bill Frels 751,440 sh (-0.38%)
Chuck Royce 733,300 sh (-5.17%)
» More
Q3 2013

SRDX Guru Trades in Q3 2013

Steven Cohen 9,329 sh (New)
Jim Simons 425,738 sh (+7.09%)
Chuck Royce 733,300 sh (unchged)
Paul Tudor Jones Sold Out
Bill Frels 750,540 sh (-0.12%)
Joel Greenblatt 54,907 sh (-8.42%)
» More
Q4 2013

SRDX Guru Trades in Q4 2013

Mario Gabelli 15,617 sh (New)
Jim Simons 455,138 sh (+6.91%)
Chuck Royce 733,300 sh (unchged)
Steven Cohen Sold Out
Bill Frels 745,690 sh (-0.65%)
Joel Greenblatt 46,744 sh (-14.87%)
» More
Q1 2014

SRDX Guru Trades in Q1 2014

Mario Gabelli 33,300 sh (+113.23%)
Jim Simons 510,395 sh (+12.14%)
Chuck Royce 733,300 sh (unchged)
Joel Greenblatt Sold Out
Bill Frels 739,540 sh (-0.82%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 Sold Out 0.03%$22.14 - $25.79 $ 20.44-16%0
Mario Gabelli 2014-03-31 Add 113.23%$22.14 - $25.79 $ 20.44-16%33300
Mario Gabelli 2013-12-31 New Buy$21.61 - $25.135 $ 20.44-13%15617
Joel Greenblatt 2013-06-30 Add 38.66%0.01%$19.74 - $27.55 $ 20.44-18%59954
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 20.443%53262
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 20.443%53262
Joel Greenblatt 2012-09-30 Add 60.21%0.04%$15.38 - $20.78 $ 20.4413%71768
Mario Gabelli 2012-09-30 Sold Out 0.03%$15.38 - $20.78 $ 20.4413%0
PRIMECAP Management 2012-06-30 Sold Out 0.0015%$13.6 - $17.22 $ 20.4437%0
Joel Greenblatt 2012-03-31 Add 200.69%0.04%$13.86 - $16.06 $ 20.4449%44610
Joel Greenblatt 2011-12-31 New Buy0.03%$8.86 - $14.99 $ 20.4479%14836
PRIMECAP Management 2011-12-31 Reduce -73.57%$8.86 - $14.99 $ 20.4479%66000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.60
SRDX's P/E(ttm) is ranked higher than
86% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 22.60 )
SRDX' s 10-Year P/E(ttm) Range
Min: 8.5   Max: 687.94
Current: 22.6

8.5
687.94
P/B 3.05
SRDX's P/B is ranked higher than
79% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.93 vs. SRDX: 3.05 )
SRDX' s 10-Year P/B Range
Min: 0.98   Max: 7.77
Current: 3.05

0.98
7.77
P/S 5.20
SRDX's P/S is ranked higher than
67% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. SRDX: 5.20 )
SRDX' s 10-Year P/S Range
Min: 2.16   Max: 13.82
Current: 5.2

2.16
13.82
PFCF 19.10
SRDX's PFCF is ranked higher than
90% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 19.10 )
SRDX' s 10-Year PFCF Range
Min: 8.44   Max: 511.5
Current: 19.1

8.44
511.5
EV-to-EBIT 13.85
SRDX's EV-to-EBIT is ranked higher than
88% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 13.85 )
SRDX' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 253.6
Current: 13.85

4.5
253.6
Shiller P/E 53.88
SRDX's Shiller P/E is ranked higher than
90% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 53.88 )
SRDX' s 10-Year Shiller P/E Range
Min: 16.9   Max: 158.8
Current: 53.88

16.9
158.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.60
SRDX's Price/Net Cash is ranked higher than
89% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 9.60 )
SRDX' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 700
Current: 9.6

3.9
700
Price/Net Current Asset Value 8.05
SRDX's Price/Net Current Asset Value is ranked higher than
88% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 8.05 )
SRDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.7   Max: 763
Current: 8.05

3.7
763
Price/Tangible Book 3.48
SRDX's Price/Tangible Book is ranked higher than
83% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.00 vs. SRDX: 3.48 )
SRDX' s 10-Year Price/Tangible Book Range
Min: 1.26   Max: 18.49
Current: 3.48

1.26
18.49
Price/DCF (Projected) 1.46
SRDX's Price/DCF (Projected) is ranked higher than
92% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 1.46 )
SRDX' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.62
Current: 1.46

0.53
4.62
Price/Median PS Value 0.75
SRDX's Price/Median PS Value is ranked higher than
92% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.35 vs. SRDX: 0.75 )
SRDX' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 6.92
Current: 0.75

0.36
6.92
Price/Graham Number 1.82
SRDX's Price/Graham Number is ranked higher than
90% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 1.82 )
SRDX' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 12.63
Current: 1.82

0.9
12.63
Earnings Yield (Greenblatt) 7.20
SRDX's Earnings Yield (Greenblatt) is ranked higher than
74% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. SRDX: 7.20 )
SRDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 22
Current: 7.2

0.4
22
Forward Rate of Return (Yacktman) 3.24
SRDX's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.89 vs. SRDX: 3.24 )
SRDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.8   Max: 62.5
Current: 3.24

0.8
62.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
SurModics, Inc. is a Minnesota Corporation. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company's core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. It partners with many of the emerging medical device, pharmaceutical and life science companies to develop and commercialize innovative products designed to improve patient outcomes. In the product lines in which The Company competes (protein stabilization reagents, substrates, recombinant autoimmune antigens and surface chemistry technologies), it faces an array of competitors ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of products. Although its drug delivery and surface modification technologies themselves are not directly regulated by the Food and Drug Administration, the medical devices, pharmaceutical and biotechnology products incorporating its technologies are subject to FDA regulation.
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 
SurModics Reports First Quarter 2009 Results Jan 28 2009 
SurModics to Webcast Fiscal 2009 First Quarter Earnings Conference Call January 28 Jan 14 2009 

More From Other Websites
SurModics Introduces Non-Corrosive, Non-Hazardous TMB Stop Solution Jun 05 2014
Zacks' Bear Of The Day: SurModics May 23 2014
Tata Motors, SurModics, Pandora, Apple and Google highlighted as Zacks Bull and Bear of the Day May 23 2014
Bear of the Day: SurModics (SRDX) May 23 2014
SURMODICS INC Financials May 16 2014
SurModics management to meet with Barrington May 15 2014
SurModics (SRDX): Moving Average Crossover Alert May 15 2014
SURMODICS INC Files SEC form 10-Q, Quarterly Report May 08 2014
Marginal Earnings Beat at SurModics, Sales Miss May 02 2014
SurModics' CEO Discusses F2Q2014 Results - Earnings Call Transcript May 01 2014
SurModics, Inc. Earnings Call scheduled for 5:00 pm ET today May 01 2014
SURMODICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 01 2014
SurModics Reports Second Quarter Fiscal 2014 Results May 01 2014
Q2 2014 SurModics, Inc. Earnings Release - After Market Close May 01 2014
SurModics to Webcast Second Quarter 2014 Earnings Conference Call on May 1 Apr 22 2014
Edwards' Sapien XT Betters Medtronic Heart Valve Apr 03 2014
Covidien Touches New 52-Week High Mar 31 2014
Agios Pharmaceuticals (AGIO) in Focus: Stock Tumbles 8.1% Mar 12 2014
GW Pharmaceuticals (GWPH) Jumps: Stock Rises 6.6% Mar 12 2014
Analyst Favorites With Strong Buyback Activity: SurModics Ranks As A Top Pick Feb 19 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide